Pasireotide (Signifor LAR)

Canada’s Drug Agency (CDA-AMC) recommends that Signifor LAR be reimbursed by public drug plans for the treatment of acromegaly if certain conditions are met. Signifor LAR should only be covered to treat patients who have a confirmed diagnosis of acromegaly and are ineligible for, have contraindications to, or have demonstrated a lack of response to surgery, and who have shown inadequate disease control with a first-generation somatostatin analogue (SSA) for a 6-month trial. Signifor LAR should only be reimbursed if prescribed by specialists who have expertise in the diagnosis and management of acromegaly and if the cost of Signifor LAR does not exceed the drug program cost of treatment with a first-generation SSA for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative.